BACKGROUND: The usefulness of @entity228 therapy for @entity299 has not yet been fully clarified. METHODS: Of 40 @entity1 diagnosed with @entity299 , twenty @entity1 complicated by @entity713 but normal cardiac function (left ventricular ejection fraction > or = 50%) were divided retrospectively into one group (n = 7) receiving @entity288 and another (n = 13) not receiving these agents. Over a mean observation period of 79.4 +/- 39.9 months, long-term outcome and laboratory findings were compared between the two groups and side effects also were noted. RESULTS: There were no deaths in the @entity228 -treated group. In the untreated group, 2 @entity1 died (15.4%). @entity713 resolved in 4 of the 7 @entity1 in the treated group (57.1%), but did not resolve or improve in any of the untreated @entity1 (p < 0.05). Left ventricular ejection fraction did not differ significantly between the treated and untreated groups at the time of initial evaluation (66.7 +/- 6.5% vs. 60.5 +/- 6.4%). In the follow-up period, a marked decline in the ejection fraction had occurred in the untreated group (37.6 +/- 17.3%), but not in the treated group (62.1 +/- 4.4%; p < 0.005). @entity1165 was not present at the initial assessment in any @entity1 in either group. In the follow-up period, @entity1165 occurred in only 1 of 7 treated @entity1 (14.3%), but was present in 8 of 13 untreated @entity1 (61.5%; p < 0.05). However, side effects of @entity228 therapy were noted in 6 of the 7 treated @entity1 (85.7%). CONCLUSION: Our findings suggest that @entity288 are useful in the treatment of @entity299 complicated by @entity713 but with normal cardiac function. However, these agents must be used with caution, with the maintenance dose kept as low as possible.

Efficacy of @entity288 in sarcoidosis presenting with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['Ventricular tachycardia', 'ventricular tachycardia'] @entity713 :: ('MESH:D054537', 'Disease') :: ['atrioventricular block', 'Atrioventricular block'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac sarcoidosis'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity713 :: (MESH:D054537,Disease) :: ['atrioventricular block']
